Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043]

Suggested remit: To appraise the clinical and cost effectiveness of lecanemab within its marketing authorisation for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease.

Status:

In progress

Technology type:

Medicine

Decision:

Selected

Reason for decision:

Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources

Process:

STA Standard

ID number:

4043

Project Team

Project lead

Kate Moore

Email enquiries

If you have any queries please email TACommD@nice.org.uk

External Assessment Group:

Kleijnen Systematic Reviews Ltd

Stakeholders

Companies sponsors

Eisai, Biogen (lecanemab)

Others

Department of Health and Social Care

 

NHS England

 

UCL Dementia Research Centre

 

Welsh Government

Patient carer groups

Alzheimer’s Research UK

 

Alzheimer's Society

 

Dementia UK

Professional groups

Association of British Neurologists

 

British Nuclear Medicine Society

 

College of Mental Health Pharmacy

 

Faculty of Public Health

 

Royal College of Physicians

 

Royal College of Psychiatrists

 

Royal College of Radiologists

 

UK Clinical Pharmacy Association

Associated public health groups

None

Comparator companies

Accord Healthcare (donepezil, memantine) (confidentiality agreement not signed, not participating)

 

Accord-UK (donepezil, galantamine, memantine) (confidentiality agreement not signed, not participating)

 

Aspire Pharma (galantamine) (confidentiality agreement not signed, not participating)

 

Aurobindo Pharma – Milpharm (donepezil, galantamine) (confidentiality agreement not signed, not participating)

 

Cipla (donepezil) (confidentiality agreement not signed, not participating)

 

Dr Reddy’s Laboratories (galantamine, memantine, rivastigmine) (confidentiality agreement not signed, not participating)

 

Eisai (donepezil) (confidentiality agreement not signed, not participating)

 

Fontus Health (galantamine) (confidentiality agreement not signed, not participating)

 

Genus Pharmaceuticals (memantine) (confidentiality agreement not signed, not participating)

 

Glenmark Pharmaceuticals (memantine) (confidentiality agreement not signed, not participating)

 

Kent Pharma (rivastigmine) (confidentiality agreement not signed, not participating)

 

Lundbeck (memantine) (confidentiality agreement not signed, not participating)

 

Lupin Healthcare (memantine) (confidentiality agreement not signed, not participating)

 

Mylan (donepezil, memantine, rivastigmine) (confidentiality agreement not signed, not participating)

 

Novartis Pharmaceuticals (rivastigmine) (confidentiality agreement not signed, not participating)

 

Ranbaxy, a Sun Pharmaceutical company (donepezil) (confidentiality agreement not signed, not participating)

 

Rosemont Pharmaceuticals (donepezil, memantine, rivastigmine) (confidentiality agreement not signed, not participating)

 

Sandoz (galantamine, rivastigmine) (confidentiality agreement not signed, not participating)

 

Takeda (galantamine) (confidentiality agreement not signed, not participating)

 

Thame Laboratories (galantamine) (confidentiality agreement not signed, not participating)

 

Zentiva (memantine, galantamine) (confidentiality agreement not signed, not participating)

General commentators

All Wales Therapeutics and Toxicology Centre

 

British National Formulary

 

Department of Health, Social Services and Public Safety for Northern Ireland

 

Healthcare Improvement Scotland

 

Medicines and Healthcare products Regulatory Agency

 

NHS Wales Joint Commissioning Committee

 

Scottish Medicines Consortium

Relevant research groups

Cambridge Public Health

 

LifeArc

 

Research Institute of the Care of Older People

Timeline

Key events during the development of the guidance:

For further information on our processes and methods, please see our CHTE processes and methods manual